Alnylam Gains on Treatment Data for Deadly Nerve Disease
This article is for subscribers only.
Alnylam Pharmaceuticals Inc., the developer of a treatment for a rare genetic disorder, rose the most ever after the drug showed promise in an early clinical trial.
Alnylam increased 53 percent to $19.16 at the close in New York, the largest one-day gain since it began trading in 2004. The Cambridge, Massachusetts-based company said today that its experimental drug for TTR-mediated amyloidosis reduced levels of the protein that causes the disease by as much as 94 percent in 17 healthy volunteers.